Synonyms: Ebglyss® | MILR1444A | RG3637 | TNX-650
lebrikizumab is an approved drug (EMA (2023))
Compound class:
Antibody
Comment: Lebrikizumab is a an anti-IL-13 monoclonal antibody.
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record. |
No information available. |
Summary of Clinical Use |
This antibody was originally tested as a treatment for refractory Hodgkin's lymphoma but was later repurposed as a potential asthma treatment [2]. The antibody entered Phase 2 trial for idiopathic pulmonary fibrosis (IPF) and Phase 3 trial for asthma. Business reports online indicate that Roche have discontinued lebrikizumab development in IPF following mixed results from their trials [1]. Click here to view ClinicalTrails.gov's listing of current lebrikizumab trials. Lebrikizumab was redirected for inflammatory skin conditions. The FDA rejected a Biologics License Application (BLA) for lebrikizumab for the treatment of atopic dermatitis in late 2023, but the EMA approved its use for this indication in November 2023. |
Mechanism Of Action and Pharmacodynamic Effects |
IL-13 induces airway hyperresponsiveness, goblet cell metaplasia and mucus hypersecretion in allergic lung diseases such as asthma [6]. These changes contribute to airway obstruction. Lebrikizumab was designed to neutralise circulating IL-13, thereby reducing disease symptoms [5]. |